JPRN-UMIN000008496招募中2 期
A Phase II trial of Panitumumab with irinotecan/S-1(IRIS) as 1st-line chemotherapy for KRAS wild type metastatic colorectal cancer - TOHOKU POWER trial
Tohoku-Six Universities Research Group by Experts(T-SURGE)0 个研究点目标入组 45 人开始时间: 2012年7月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who have allergy for drugs. 2. Patients who have other malignancies. 3. Infectuins in active. 4. Patients who have past histories of bowel perforation and/or bowel obstruction in one year before registration. 5. Serious complications (e.g.,interstitial pneumonitis, pulmonary fibrosis, heart failure, renal failure, hepatic failure or uncontrolled high blood pressure or diabetes mellitus). 6. Pleural effusion and/or ascites to need treatment. 7. Watery diarrhea. 8. Patients who have given a dose of flucytosine or atazanavir sulfate. 9. Patients who have brain metastases. 10. Pregnant woman, nursing mothers, possibly pregnant woman and wishing to become pregnant. 11. Patients who have severe mental disease. 12. The Patient that a study responsibility physician judged to be inappropriate.
研究者
相似试验
已完成
2 期
phase II study of panitumumab with irinotecan as third-line treatment for advanced colorectal cancer patientsmetastatic colorectal cancerJPRN-UMIN000005180Yokohama city university37
招募中
不适用
A phase II study of Panitumumab combined with Irinotecan and S-1 as second line therapy in metastatic colorectal cancer patients with KRAS wild typeJPRN-UMIN000004697Kanagawa Cancer Center30
进行中（未招募）
1 期
A Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab PlusAMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin- or Irinotecan- and Oxaliplatin-containing Regimens to Evaluate Mechanisms of Acquired Resistance to PanitumumabMetastatic colorectal cancerMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2008-004752-77-FRAmgen Inc76
进行中（未招募）
1 期
A Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin- or Irinotecan- and Oxaliplatin-containing Regimens to Evaluate Mechanisms of Acquired Resistance to Panitumumab - 20070820Metastatic colorectal cancer expressing wild type (wt) KRAS and refractory to irinotecan- and oxaliplatin-containing regimens, or refractory to oxaliplatin-containing regimens.MedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2008-004752-77-ITAmgen Inc.76
进行中（未招募）
不适用
Ph2 Biomarker (Mechanism of K-ras Dependency) in Wt KRAS Metastatic Colorectal Cancer PatientsMetastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2008-004752-77-DEAmgen Inc75